ADC Therapeutics SA
NYSE:ADCT
ADC Therapeutics SA
NYSE:ADCT
Price:
4.44 USD
-7.11%
Market Closed
Updated:
Apr 26, 2024
ADC Therapeutics SA
Additional Paid In Capital
|
ADC Therapeutics SA
Additional Paid In Capital Peer Comparison
Comparables:
ACIU
CRSP
BSLN
IDIA
KURN
Competitive Additional Paid In Capital Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Additional Paid In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
ADC Therapeutics SA
NYSE:ADCT
|
Additional Paid In Capital
$1.2B
|
CAGR 3-Years
6%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
AC Immune SA
NASDAQ:ACIU
|
Additional Paid In Capital
CHf474.9m
|
CAGR 3-Years
11%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Additional Paid In Capital
$2.9B
|
CAGR 3-Years
9%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Additional Paid In Capital
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Idorsia Ltd
SIX:IDIA
|
Additional Paid In Capital
CHf2.1B
|
CAGR 3-Years
25%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Additional Paid In Capital
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is ADC Therapeutics SA's Additional Paid In Capital?
Additional Paid In Capital
1.2B
USD
1.2B
USD
Based on the financial report for Dec 31, 2023, ADC Therapeutics SA's Additional Paid In Capital amounts to 1.2B USD.
What is ADC Therapeutics SA's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 5Y
21%
21%
Over the last year, the Additional Paid In Capital growth was 17%. The average annual Additional Paid In Capital growth rates for ADC Therapeutics SA have been 6% over the past three years , 21% over the past five years .
You don't have any saved screeners yet
